Loading
Life sciences · Journal article
Frontiers in Microbiology · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Fusobacterium, especially Fusobacterium nucleatum, has emerged as a metabolically active pathobiont that can affect host physiology and disease pathogenesis. Through its ability to produce and regulate various metabolites, Fusobacterium can shape immune response, cellular metabolism, and disease progression. Short-chain fatty acids (SCFAs), being part of Fusobacterium -associated metabolic changes observed during disease, are involved in microbial cross-feeding and can affect neutrophil recruitment and inflammatory signaling through free fatty acid receptors. In the case of colorectal cancer (CRC), Fusobacterium -derived metabolites can impact tumor and immune cell phenotype via a number of mechanisms, including aryl hydrocarbon receptor (AhR) activation via indole derivatives, inflammatory and metabolic signaling via hydrogen sulfide, as well as an increase in Glucose transporter 1 (GLUT1) expression, lactate production, and histone lactylation via formate-related metabolites. Besides, F. nucleatum can reshape tumor-cell metabolism, including cholesterol biosynthesis through miR-130a-3p-mediated inhibition of AMP-activated protein kinase (AMPK) signaling, whereas butyrate has been reported to counteract this metabolic phenotype in experimental CRC models. In addition, F. nucleatum -associated succinate has been shown to suppress cGAS–Interferon beta (IFN-β) signaling, thereby reducing antitumor immune activation, impairing CD8 + T-cell trafficking, and promoting immune escape and resistance to anti-Programmed Cell Death Protein 1 (PD-1) therapy. The present review provides an overview of current understanding of the biological roles of Fusobacterium -derived metabolites, focusing on SCFAs, succinate, indole derivatives, hydrogen sulfide, and formate-related metabolites.